Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-10-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the release and re-pledging of shares by the controlling shareholder of the company. It details the number of shares involved, pledge dates, pledgees, and the impact on shareholding and financing. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory announcement about share pledging activities, which fits the category of Capital/Financing Update (CAP). The document length is 2639 characters, which is typical for such announcements and not a full financial report. Therefore, the classification is CAP with high confidence.
2024-10-18 Chinese
关于持股5%以上股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the pledgee, and the terms of the pledge. There is no financial report, earnings data, or management discussion. The content is focused on shareholding and financing activities related to share pledges. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2024-09-20 Chinese
关于全资子公司公司医疗器械注册证变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in the medical device registration certificate for a wholly-owned subsidiary of Shenzhen BGI Genomics Co., Ltd. It details the specifics of the registration certificate change issued by the National Medical Products Administration, including product name, registration number, classification, validity period, and changes in intended use. The document also discusses the potential impact and risks related to this change. The document is short (1342 characters) and is an announcement of a regulatory approval/change rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management commentary. It is not a report publication announcement since it does not mention the release or availability of a report. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a product registration change that does not fit into other specific categories like financial reports, management changes, or capital updates.
2024-09-12 Chinese
关于参与认购绍兴美越医疗产业股权投资合伙企业（有限合伙）基金份额的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen BGI Co., Ltd. regarding its participation in subscribing to shares of a medical industry equity investment partnership fund. It details the investment overview, the fund's structure, the partnership agreement, investment purpose, impact on the company, and associated risks. There are no financial statements, quarterly or annual results, or audit information presented. The document is a formal disclosure of a capital investment transaction and does not contain financial report data or earnings information. It fits the category of a Capital/Financing Update as it informs about the company's fundraising or capital structure changes through investment in a fund. The document length is sufficient and contains detailed information about the investment but is not a full financial report or earnings release.
2024-09-10 Chinese
关于控股股东部分股份解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the release and re-pledging of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares involved, pledge dates, pledgees, and the impact on the company's shareholding structure. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory disclosure about share pledge status and related risks, typical of a share pledge or capital structure update. It is not a full financial report, earnings release, or management report. The content fits best under the category of Capital/Financing Update (CAP), as it concerns financing activities related to share pledges by a major shareholder.
2024-09-09 Chinese
关于部分董事、高级管理人员增持公司股份计划增持金额过半的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the progress of a share purchase plan by certain directors and senior management of Shenzhen BGI Genomics Co., Ltd. It details the amounts and shares acquired, the timeline of the share purchases, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a disclosure about transactions in the company's own shares by insiders (directors and senior management). Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is 3276 characters, which is consistent with an announcement rather than a full report.
2024-09-06 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.